NCLT Approves Beaufond Industries' Resolution Plan for Kobo Biotech Limited
The NCLT Hyderabad Bench approved the resolution plan of Beaufond Industries Limited for Kobo Biotech Limited on May 11, 2026, with a total resolution amount of INR 70.11 crores. Financial creditors are to receive INR 67.78 crores as part of the upfront payment, along with an equity upside of approximately 3% of total shareholding. The approved composite scheme involves amalgamation and demerger, resulting in a post-resolution total share capital of 3,93,47,700 shares at a face value of Rs. 10 each, with promoter shareholding at 57.23%. All pre-existing liabilities of the Corporate Debtor shall stand extinguished upon implementation of the plan.
*this image is generated using AI for illustrative purposes only.
Kobo Biotech Limited has informed stakeholders that the Hon'ble National Company Law Tribunal (NCLT), Hyderabad Bench, has approved the resolution plan submitted by Beaufond Industries Limited (the "Successful Resolution Applicant" or "RA") vide its order dated May 11, 2026, in IA (Plan) No. 01 of 2026 in CP (IB) No. 277/7/HDB/2023 under the Insolvency and Bankruptcy Code, 2016. The Committee of Creditors had approved the resolution plan during its meeting held on March 17, 2026, following which it was submitted before the NCLT. The disclosure has been made in compliance with Regulation 30 read with Schedule III, Para A of Part A, Clause 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Pre- and Post-CIRP Financial Position
The following table summarises the key financial metrics of the Corporate Debtor and the Successful Resolution Applicant as per their respective last audited financial statements:
| Metric: | Details |
|---|---|
| Net Worth of Corporate Debtor (as on March 31, 2024): | INR 132.91 crores |
| Total Assets of Corporate Debtor (as on March 31, 2024): | INR 71.39 crores |
| Net Worth of Successful Resolution Applicant (as on March 31, 2025): | INR 333.18 crores |
The post-CIRP net worth of the Corporate Debtor shall be ascertained post-implementation of the approved resolution plan. The net worth of Beaufond Industries Limited, as per its last audited financial statements and CA-certified net worth certificate as on March 31, 2025, stood at INR 333.18 crores, which will be merged with the Corporate Debtor as part of the approved resolution plan.
Resolution Amount and Creditor Payments
The approved resolution plan entails a total resolution amount of INR 70.11 crores, payable as upfront payment within X + 60 days (where X is the NCLT Approval Date). The breakdown of payments is as follows:
| Particulars: | Upfront Payment (X + 60 days) | Total Amount (INR In Crores) |
|---|---|---|
| Unpaid CIRP Cost incl. Interim Finance (if any): | 2,30,00,000 (at actuals) | 2.30 |
| Secured Financial Creditors and Unsecured Financial Creditors: | 67,78,00,000 | 67.78 |
| Operational Creditors (Workmen and Employees): | 1,00,000 | 0.01 |
| Operational Creditors – Government Dues/Statutory Dues: | 1,00,000 | 0.01 |
| Operational Creditors (Other than workmen and statutory dues): | 1,00,000 | 0.01 |
| Resolution Amount: | 70,11,00,000 | 70.11 |
The Resolution Applicant proposes to pay a total resolution plan amount of Rs. 67,81,00,000 (Rupees sixty-seven crores and eighty-one lakhs only), of which INR 67,78,00,000 (Rupees sixty-seven crores and seventy-eight lakhs only) is proposed to the Financial Creditors, plus an equity upside to the assenting financial creditors against the Converted Debt, estimated at around 3% of total shareholding on a fully-diluted basis, each in the Corporate Debtor and the Resulting Company.
Pre- and Post-Resolution Shareholding Pattern
The shareholding of the Corporate Debtor prior to implementation of the approved resolution plan is as follows:
| Shareholders: | No. of Shares | Share Capital (In INR) | Shareholding Percentage |
|---|---|---|---|
| Promoter and Promoter Group: | 10709100 | 10,70,91,000 | 44.95% |
| Public Shareholders: | 13115900 | 13,11,59,000 | 55.05% |
| Total: | 23825000 | 23,82,50,000 | 100.00% |
Pursuant to the Composite Scheme involving amalgamation and demerger, the post-resolution shareholding of the Corporate Debtor shall be restructured as follows:
| Nature of Issuance: | Shareholders | No. of Shares | Share Capital (In INR) | Face Value | Shareholding Percentage |
|---|---|---|---|---|---|
| Fresh Issuance (Promoter Category): | Issuance to the promoter shareholders of the RA | 2,25,20,231 | 22,52,02,310 | 10 | 57.23% |
| Fresh Issuance In public category: | Issuance to the minority shareholders of the RA not holding more than 3% of the shares in the RA | 1,48,60,084 | 14,86,00,840 | 10 | 37.77% |
| KBL Retained Public Shareholders / Existing Public Shareholders: | Public | 7,86,954 | 78,69,540 | 10 | 2.00% |
| Secured and Unsecured Financial Creditors of the CD: | Public | 11,80,431 | 1,18,04,310 | 10 | 3% each in Corporate Debtor and the Resulting Company |
| Total: | 3,93,47,700 | 39,34,77,000 | 10 | 100% |
Upon the Amalgamation Effective Date, the Merged Entity will issue and allot new equity shares to equity shareholders of the Transferor Company in the ratio of 268.81:1, i.e., 268.81 equity shares of Rs. 10 each credited as fully paid up in the Merged Entity for every 1 equity share of Rs. 10 each fully paid up held in the Transferor Company. Upon the Demerger Effective Date, the Resulting Company will issue and allot new equity shares in the ratio of 1:1, i.e., 1 equity share of Rs. 10 each credited as fully paid up in the Resulting Company for every 1 equity share of Rs. 10 each fully paid up held in the Merged Entity.
Liability Extinguishment and Business Strategy
Pursuant to the assignment of Assigned Debt from the assenting financial creditors in favour of the Successful Resolution Applicant, and the subsequent merger of the Successful Resolution Applicant with the Corporate Debtor as contemplated under the Resolution Plan read with the Composite Scheme, all liabilities, obligations, dues, and claims of any nature whatsoever — whether admitted, crystallised, contingent, uncrystallised, secured, unsecured, known, or unknown — standing against the Corporate Debtor or its assets shall stand irrevocably extinguished, settled, and abated. No fresh or residual liabilities shall survive or be imposed on the Corporate Debtor post-implementation. The Resolution Applicant has stated that the goal is to bring the Corporate Debtor back into active operations, restore its market reputation, and make it a sustainable and profitable pharmaceutical manufacturing unit.
Governance and Minimum Public Shareholding
A duly constituted Monitoring Committee shall manage the day-to-day affairs of the Corporate Debtor until the complete hand-over of assets. The Monitoring Committee shall comprise: (i) the Resolution Professional, (ii) one nominee of the member of the Committee of Creditors having the largest voting share, and (iii) one nominee of the Resolution Applicant. Pursuant to the issue of shares as per the Resolution Plan read with the Composite Scheme, the promoter shareholding will be 57.23% and the balance will be held with public shareholders, ensuring that the shareholding held by the public exceeds the minimum threshold prescribed. No delisting plans have been approved under the resolution plan. The revised projected financials and ratios such as P/E and RONW are not known at present and will be updated post-implementation of the resolution plan.
Historical Stock Returns for Kobo Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.81% | +9.69% | +3.28% | +0.35% | +4.04% | -55.50% |
How will Beaufond Industries Limited's INR 333.18 crore net worth translate into operational turnaround capacity for Kobo Biotech's pharmaceutical manufacturing unit within the next 12-18 months?
Given that existing public shareholders retain only 2% post-restructuring, what legal or regulatory recourse do minority shareholders have to challenge the significant dilution under SEBI's framework?
Will the 268.81:1 share swap ratio trigger any SEBI open offer obligations or market surveillance concerns once the Amalgamation Effective Date is reached?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
